VRTX Vertex Pharmaceuticals Incorporated Stock Quote

VRTX [NASD]

Index	S&P 500	P/E	22.07	EPS (ttm)	10.22	Insider Own	0.10%	Shs Outstand	260.39M	Perf Week	-4.83%
Market Cap	57.64B	Forward P/E	19.67	EPS next Y	11.47	Insider Trans	-5.24%	Shs Float	259.67M	Perf Month	-1.42%
Income	2.69B	PEG	0.87	EPS next Q	2.57	Inst Own	95.70%	Short Float	1.25%	Perf Quarter	4.77%
Sales	5.99B	P/S	9.62	EPS this Y	118.10%	Inst Trans	0.15%	Short Ratio	1.46	Perf Half Y	-23.42%
Book/sh	31.24	P/B	7.22	EPS next Y	10.66%	ROA	27.80%	Target Price	285.58	Perf Year	-4.23%
Cash/sh	24.07	P/C	9.37	EPS next 5Y	25.24%	ROE	38.20%	52W Range	197.47 - 306.08	Perf YTD	-4.57%
Dividend	-	P/FCF	19.35	EPS past 5Y	28.00%	ROI	14.70%	52W High	-26.31%	Beta	0.64
Dividend %	-	Quick Ratio	3.60	Sales past 5Y	48.30%	Gross Margin	88.00%	52W Low	14.22%	ATR	5.81
Employees	3000	Current Ratio	3.70	Sales Q/Q	62.00%	Oper. Margin	44.40%	RSI (14)	43.54	Volatility	2.61% 2.42%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	1060.40%	Profit Margin	44.90%	Rel Volume	1.01	Prev Close	226.12
Shortable	Yes	LT Debt/Eq	0.07	Earnings	Oct 29 AMC	Payout	0.00%	Avg Volume	2.23M	Price	225.55
Recom	1.90	SMA20	-3.04%	SMA50	-0.32%	SMA200	-12.40%	Volume	2,241,571	Change	-0.25%

Dec-30-20

Initiated

Daiwa Securities

Outperform

$250

Nov-30-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$247 → $267

Nov-20-20

Initiated

Bernstein

Outperform

$225

Oct-28-20

Initiated

UBS

Buy

$287

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$295 → $315

Jul-08-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$300

Apr-30-20

Reiterated

H.C. Wainwright

Buy

$270 → $295

Apr-28-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$250 → $260

Mar-04-20

Initiated

Barclays

Overweight

$271

Jan-31-20

Downgrade

Robert W. Baird

Outperform → Neutral

$210 → $230

Nov-19-19

Upgrade

Guggenheim

Neutral → Buy

$252

Nov-12-19

Initiated

SunTrust

Buy

$235

Oct-17-19

Resumed

BofA/Merrill

Buy

$220

Sep-03-19

Upgrade

Goldman

Neutral → Buy

$226 → $254

Aug-01-19

Downgrade

Needham

Buy → Hold

May-23-19

Resumed

Citigroup

Buy

$205

May-21-19

Initiated

Credit Suisse

Outperform

$209

Apr-12-19

Initiated

Evercore ISI

In-line

Mar-26-19

Upgrade

William Blair

Mkt Perform → Outperform

Mar-19-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

Jan-15-21 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Moves -0.25%: What You Should Know Zacks
Jan-11-21 08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals Zacks
Jan-10-21 07:05AM	The Top 3 Biotech Stocks to Buy in 2021 Motley Fool
06:06AM	3 Top Biotech Picks for 2021 Motley Fool
Jan-08-21 05:45PM	Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Zacks
Jan-07-21 09:01AM	Vertex to Present at the J.P. Morgan Healthcare Conference on January 11 Business Wire
07:00AM	Where to Invest $100,000 Right Now Motley Fool
Jan-06-21 06:25AM	Expecting a $600 Stimulus Check? These 2 Stocks Should Rebound Big Motley Fool
Jan-05-21 07:08AM	3 Recession-Proof Healthcare Stocks to Buy for 2021 Motley Fool
06:36AM	3 Nasdaq 100 Stocks That Can Make You a Boatload of Money in 2021 Motley Fool
06:00AM	Get Ready for Health-Care Stocks to Go Wild. How to Play Them. Barrons.com
Jan-04-21 09:30AM	Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study Zacks
Jan-03-21 10:13PM	Why The EPS Rating Is One Key To Picking The Best Stocks Investor's Business Daily
Jan-01-21 06:36AM	4 Unstoppable Stocks to Buy for a Biden Bull Market in 2021 Motley Fool
Dec-31-20 08:49AM	Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis Zacks
Dec-30-20 08:41AM	Is Vertex Pharmaceuticals (VRTX) a Smart Long-term Buy? Insider Monkey
Dec-29-20 07:57AM	Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 38% Discount? Simply Wall St.
Dec-28-20 08:04AM	Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada Business Wire
Dec-27-20 07:31AM	The 3 Best Healthcare Stocks to Buy for 2021 Motley Fool
Dec-26-20 05:51AM	3 Surefire Stocks to Buy With Your $600 Stimulus Check Motley Fool
Dec-24-20 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
07:02AM	Where to Invest $5,000 Right Now Motley Fool
06:45AM	The 3 Best Stocks for 2021 Motley Fool
Dec-23-20 10:09AM	Vertex (VRTX) Inks Deal with Skyhawk for Serious Diseases Zacks
06:06AM	3 Beaten-Down Growth Stocks That Can Soar in 2021 Motley Fool
Dec-22-20 12:56PM	4 Biopharma Stock Picks From Analysts for 2021 Barrons.com
11:42AM	Vertex Pharmaceuticals Enters New Partnership With RNA Expert Skyhawk Therapeutics Motley Fool
08:30AM	Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases Business Wire
Dec-21-20 04:24PM	Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure Dives Investor's Business Daily
02:30PM	Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations Business Wire
Dec-19-20 06:09AM	3 Top Biotech Stocks to Buy Right Now Motley Fool
Dec-18-20 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Moves -0.08%: What You Should Know Zacks
Dec-15-20 07:03AM	Where Will CRISPR Therapeutics Be in 10 Years? Motley Fool
Dec-14-20 10:37AM	Billionaire David Shaw Bets Big on These 3 Healthcare Stocks TipRanks
05:51AM	3 Surefire Stocks to Buy When the Stock Market Inevitably Crashes Motley Fool
Dec-13-20 06:45AM	If You Have $1,000 and 5 Years to Wait, Buy These 2 Stocks Now Motley Fool
Dec-12-20 03:39PM	Watch Out bluebird bio, CRISPR Is on Your Heels Motley Fool
Dec-11-20 05:45PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know Zacks
Dec-10-20 12:47PM	Editas (EDIT) Submits Application to Start Study on EDIT-301 Zacks
Dec-09-20 04:02PM	Top Biotech Stocks for Q1 2021 Investopedia
01:10PM	Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News Zacks
06:09AM	The Best Biotech Stock on the Market Right Now Motley Fool
Dec-08-20 04:45PM	The Latest Lap in Bluebirds and Crisprs Race to Cure Sickle Cell Barrons.com
Dec-07-20 09:19AM	CRISPR (CRSP) Up on Promising Data for Gene Therapy CTX001 Zacks
08:49AM	Is Vertex Pharmaceuticals (VRTX) A Good Stock To Buy Now? Insider Monkey
Dec-05-20 12:30PM	CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine GlobeNewswire
12:30PM	Crispr Gene Editing Shows Promise in Blood Disease Study Updates Bloomberg
Dec-04-20 10:43AM	Red-Hot Biotechs to Take Spotlight at Blood Disorder Meeting Bloomberg
Dec-03-20 08:05AM	Fastest-Growing Companies: 27 Stocks Expecting Up To 711% EPS Growth In 2020 Investor's Business Daily
07:25AM	Is Vertex Pharmaceuticals Stock a Buy? Motley Fool
Dec-02-20 12:56PM	Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More Zacks
Dec-01-20 09:00AM	CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 in Sickle Cell Disease and Beta Thalassemia GlobeNewswire
Nov-30-20 10:44AM	Vertex (VRTX) Symkevi/Kalydeco Label Expansion Gets EU Nod Zacks
Nov-27-20 03:00AM	Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years Business Wire
Nov-21-20 05:51AM	5 Growth Stocks to Buy for a Biden Bull Market Motley Fool
Nov-20-20 10:45AM	Odds Of Vertex's Pipeline Success Aren't Dismal As Some Fear, Bernstein Says Benzinga
09:33AM	Nasdaq-100 Laggards Could Offer Timely Short Sales Investopedia
09:32AM	Benzinga's Top Upgrades, Downgrades For November 20, 2020 Benzinga
Nov-15-20 07:04AM	2 Top Pharma Stocks to Watch in November Motley Fool
Nov-13-20 04:01PM	Vertex Recommends Rejection of Mini-Tender Offer From TRC Capital Investment Corporation Business Wire
05:51AM	Got $250? 3 High-Growth Stocks on Sale to Buy Now Motley Fool
Nov-12-20 04:01PM	Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19 Business Wire
06:53AM	5 Top Healthcare Stocks to Buy in November Motley Fool
Nov-08-20 11:20PM	Here's Why Vertex Pharmaceuticals Fell 23.4% in October Motley Fool
Nov-06-20 06:23AM	Can bluebird bio Recover From Another Major Setback? Motley Fool
Nov-05-20 04:00AM	Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age Business Wire
Nov-04-20 04:17PM	Why This Gene-Editing Player Just Outpaced Bullish Biotech Stocks Investor's Business Daily
03:16PM	Why This Gene-Editing Player Just Outpaced Bullish Biotech Stocks Investor's Business Daily
02:25PM	Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More Zacks
02:11PM	CRISPR and Vertex Release Additional Data for Blood Disease Treatment Motley Fool
09:15AM	CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition GlobeNewswire
Nov-01-20 06:57AM	3 Reasons to Buy Vertex Pharmaceuticals and 1 Reason Not To Motley Fool
06:15AM	3 Reasons Vertex Is Still a Buy After Its Recent Pipeline Setback Motley Fool
Oct-30-20 12:32PM	Vertex (VRTX) Beats on Q3 Earnings & Sales, Ups Sales View Zacks
06:05AM	Why Vertex Hit a Home Run With Its Q3 Results, but Few Are Cheering Motley Fool
05:01AM	Vertex Pharmaceuticals Inc (VRTX) Q3 2020 Earnings Call Transcript Motley Fool
Oct-29-20 05:35PM	Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue Estimates Zacks
04:52PM	Recap: Vertex Pharmaceuticals Q3 Earnings Benzinga
04:01PM	Vertex Reports Third-Quarter 2020 Financial Results Business Wire
02:30PM	Vertex Pharmaceuticals, Inc.to Host Earnings Call ACCESSWIRE
Oct-28-20 12:55PM	What's in Store for ADMA Biologics' (ADMA) Q3 Earnings? Zacks
12:38PM	Benzinga's Top Upgrades, Downgrades For October 28, 2020 Benzinga
07:00AM	Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals Motley Fool
Oct-27-20 11:29AM	Moderna (MRNA) to Report Q3 Earnings: What's in the Cards? Zacks
10:08AM	3 Biotech Stocks I'd Buy Right Now Motley Fool
Oct-26-20 01:06PM	Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day Zacks
12:52PM	Were These Hedge Funds Right About Selling Vertex Pharmaceuticals Incorporated (VRTX)? Insider Monkey
09:19AM	What's in the Cards for Cassava (SAVA) This Earnings Season? Zacks
08:45AM	Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings? Zacks
08:00AM	Best ESG Companies By Category: These Are The Top 3 ESG Stocks In 8 Industries Investor's Business Daily
08:00AM	Best ESG Companies: Top 50 Stocks For Environmental, Social And Governance Values Investor's Business Daily
Oct-23-20 07:42AM	Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings? Zacks
Oct-22-20 12:34PM	Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
11:22AM	Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates Zacks
Oct-21-20 10:46AM	AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review Zacks
09:03AM	Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity Zacks
08:55AM	Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co Zacks
Oct-20-20 11:30AM	Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
10:40AM	Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M Zacks
09:26AM	Pick These 5 Stocks With Superb Interest Coverage Ratio Zacks

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sachdev Amit	EVP, Chief Patient Officer	Nov 16	Sale	223.53	42	9,388	35,103	Nov 18 04:16 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 16	Sale	223.53	91	20,341	26,838	Nov 18 04:12 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 16	Sale	223.64	7	1,565	35,179	Nov 18 04:11 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 16	Sale	223.47	38	8,492	28,902	Nov 18 04:10 PM
SACHS BRUCE I	Director	Nov 10	Buy	217.36	15,000	3,260,465	26,210	Nov 12 08:18 AM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Option Exercise	86.52	2,330	201,592	29,168	Nov 06 04:09 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Sale	217.74	2,330	507,329	26,838	Nov 06 04:09 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Option Exercise	86.52	1,553	134,366	36,732	Nov 05 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Sale	211.92	1,553	329,115	35,179	Nov 05 04:16 PM
Bhatia Sangeeta N.	Director	Oct 05	Option Exercise	126.68	8,729	1,105,790	14,424	Oct 07 04:11 PM
Bhatia Sangeeta N.	Director	Oct 05	Sale	266.79	10,516	2,805,518	3,908	Oct 07 04:11 PM
Silva Paul M	SVP & Controller	Aug 06	Option Exercise	169.39	1,078	182,598	16,010	Aug 10 04:24 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Option Exercise	155.57	1,223	190,262	30,125	Aug 10 04:13 PM
Kewalramani Reshma	CEO & President	Aug 06	Option Exercise	179.68	2,073	372,482	28,699	Aug 10 04:19 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Option Exercise	155.57	1,223	190,262	28,061	Aug 10 04:22 PM
Silva Paul M	SVP & Controller	Aug 06	Sale	271.17	1,078	292,319	14,932	Aug 10 04:24 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Sale	271.19	1,223	331,663	28,902	Aug 10 04:13 PM
Kewalramani Reshma	CEO & President	Aug 06	Sale	271.20	2,073	562,205	26,626	Aug 10 04:19 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Sale	271.20	1,223	331,672	26,838	Aug 10 04:22 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Option Exercise	86.52	2,330	201,592	31,232	Aug 05 04:14 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Option Exercise	86.52	1,553	134,366	36,732	Aug 05 04:17 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Option Exercise	86.52	2,330	201,592	29,168	Aug 05 04:20 PM
Silva Paul M	SVP & Controller	Aug 03	Option Exercise	86.52	809	69,995	15,741	Aug 05 04:24 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Option Exercise	86.52	1,941	167,935	37,044	Aug 05 04:51 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Sale	278.24	2,330	648,290	28,902	Aug 05 04:14 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Sale	278.39	1,553	432,337	35,179	Aug 05 04:17 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Sale	278.28	2,330	648,402	26,838	Aug 05 04:20 PM
Silva Paul M	SVP & Controller	Aug 03	Sale	278.30	809	225,142	14,932	Aug 05 04:24 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Sale	278.28	1,941	540,137	35,103	Aug 05 04:51 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Jul 13	Option Exercise	90.29	2,125	191,866	28,963	Jul 15 04:41 PM
Silva Paul M	SVP & Controller	Jul 13	Option Exercise	90.29	860	77,649	15,792	Jul 15 04:51 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Jul 13	Sale	292.05	2,125	620,610	26,838	Jul 15 04:41 PM
Silva Paul M	SVP & Controller	Jul 13	Sale	292.03	860	251,145	14,932	Jul 15 04:51 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jul 10	Sale	293.15	700	205,206	16,126	Jul 14 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Jul 07	Option Exercise	173.51	2,786	483,403	37,965	Jul 09 04:13 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Jul 07	Sale	300.00	2,786	835,800	35,179	Jul 09 04:13 PM
LEIDEN JEFFREY M	Executive Chairman	Jun 30	Sale	286.15	32,792	9,383,304	2,261	Jul 02 04:15 PM
Bhatia Sangeeta N.	Director	Jun 02	Sale	282.88	952	269,298	5,695	Jun 03 04:22 PM
Kewalramani Reshma	CEO & President	May 15	Sale	284.17	99	28,132	26,626	May 19 04:35 PM
Tatsis Ourania	EVP, Chief Regulatory Officer	May 15	Sale	284.00	120	34,080	12,738	May 19 04:33 PM
Silva Paul M	SVP & Controller	May 15	Sale	284.00	151	42,885	14,932	May 19 04:31 PM
Sachdev Amit	EVP, Chief Patient Officer	May 15	Sale	284.41	58	16,496	35,103	May 19 04:29 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 15	Sale	284.40	68	19,339	26,838	May 19 04:28 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	May 15	Sale	283.98	113	32,089	35,179	May 19 04:22 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 15	Sale	284.37	82	23,318	28,902	May 19 04:21 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 12	Option Exercise	187.53	1,304	244,539	30,206	May 14 04:17 PM
LEIDEN JEFFREY M	Executive Chairman	May 12	Option Exercise	137.52	88,532	12,174,639	129,353	May 14 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 12	Sale	287.33	1,304	374,678	28,902	May 14 04:17 PM
LEIDEN JEFFREY M	Executive Chairman	May 12	Sale	283.47	94,370	26,751,440	34,983	May 14 04:19 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 11	Option Exercise	187.53	1,304	244,539	28,142	May 13 04:18 PM
Sachdev Amit	EVP, Chief Patient Officer	May 11	Option Exercise	131.89	10,665	1,406,607	45,768	May 13 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 11	Sale	286.00	1,304	372,944	26,838	May 13 04:18 PM
Sachdev Amit	EVP, Chief Patient Officer	May 11	Sale	282.61	10,665	3,014,014	35,103	May 13 04:20 PM
SACHS BRUCE I	Director	May 07	Option Exercise	70.55	45,000	3,174,525	56,210	May 08 04:24 PM
LEIDEN JEFFREY M	Executive Chairman	May 07	Option Exercise	137.52	88,534	12,174,982	135,190	May 08 04:20 PM
SACHS BRUCE I	Director	May 07	Sale	269.80	45,000	12,140,806	11,210	May 08 04:24 PM
LEIDEN JEFFREY M	Executive Chairman	May 07	Sale	269.78	94,369	25,459,013	40,821	May 08 04:20 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 06	Option Exercise	155.57	1,222	190,107	30,124	May 08 04:17 PM
Kewalramani Reshma	CEO & President	May 06	Option Exercise	179.67	2,074	372,638	28,700	May 08 04:19 PM
Sachdev Amit	EVP, Chief Patient Officer	May 06	Option Exercise	131.89	669	88,234	35,772	May 08 04:23 PM
Tatsis Ourania	EVP, Chief Regulatory Officer	May 06	Option Exercise	174.06	966	168,146	13,704	May 08 04:28 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 06	Option Exercise	155.57	1,222	190,107	28,060	May 08 04:22 PM
Silva Paul M	SVP & Controller	May 06	Option Exercise	169.38	1,076	182,255	16,008	May 08 04:26 PM
Silva Paul M	SVP & Controller	May 06	Sale	272.74	1,076	293,472	14,932	May 08 04:26 PM
Tatsis Ourania	EVP, Chief Regulatory Officer	May 06	Sale	272.70	966	263,431	12,738	May 08 04:28 PM
Sachdev Amit	EVP, Chief Patient Officer	May 06	Sale	275.28	669	184,162	35,103	May 08 04:23 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 06	Sale	272.64	1,222	333,165	26,838	May 08 04:22 PM
Kewalramani Reshma	CEO & President	May 06	Sale	272.85	2,074	565,882	26,626	May 08 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 06	Sale	272.66	1,222	333,195	28,902	May 08 04:17 PM
Sachdev Amit	EVP, Chief Patient Officer	May 05	Option Exercise	131.89	13,356	1,761,523	48,459	May 06 04:43 PM
LEIDEN JEFFREY M	Executive Chairman	May 05	Option Exercise	137.52	88,537	12,175,273	141,028	May 07 04:24 PM
Sachdev Amit	EVP, Chief Patient Officer	May 05	Sale	270.01	13,356	3,606,232	35,103	May 06 04:43 PM
LEIDEN JEFFREY M	Executive Chairman	May 05	Sale	269.94	94,372	25,475,037	46,656	May 07 04:24 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 04	Option Exercise	86.52	2,330	201,592	31,232	May 06 04:17 PM
Sachdev Amit	EVP, Chief Patient Officer	May 04	Option Exercise	112.98	43,752	4,942,968	78,855	May 06 04:43 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 04	Option Exercise	86.52	2,330	201,592	29,168	May 06 04:25 PM
Silva Paul M	SVP & Controller	May 04	Option Exercise	86.52	809	69,995	15,741	May 06 04:27 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	May 04	Option Exercise	86.52	1,553	134,366	36,732	May 06 04:38 PM
Silva Paul M	SVP & Controller	May 04	Sale	260.87	809	211,048	14,932	May 06 04:27 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 04	Sale	260.87	2,330	607,827	26,838	May 06 04:25 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 04	Sale	260.86	2,330	607,803	28,902	May 06 04:17 PM
Sachdev Amit	EVP, Chief Patient Officer	May 04	Sale	262.28	43,752	11,475,179	35,103	May 06 04:43 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	May 04	Sale	260.76	1,553	404,957	35,179	May 06 04:38 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Apr 29	Option Exercise	90.29	2,125	191,866	28,963	May 01 04:22 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Apr 29	Sale	254.95	2,125	541,769	26,838	May 01 04:22 PM
Lee Yuchun	Director	Apr 28	Option Exercise	57.27	1,125	64,429	3,000	Apr 29 04:14 PM
Lee Yuchun	Director	Apr 28	Sale	257.88	1,125	290,115	1,875	Apr 29 04:14 PM
Lee Yuchun	Director	Apr 27	Option Exercise	57.27	2,000	114,540	3,875	Apr 28 04:23 PM
Lee Yuchun	Director	Apr 27	Sale	271.21	2,000	542,419	1,875	Apr 28 04:23 PM
Lee Yuchun	Director	Apr 24	Option Exercise	57.27	2,000	114,540	3,875	Apr 28 04:23 PM
Lee Yuchun	Director	Apr 24	Sale	268.14	2,000	536,286	1,875	Apr 28 04:23 PM
Lee Yuchun	Director	Apr 23	Option Exercise	57.27	2,000	114,540	3,875	Apr 24 04:17 PM
Lee Yuchun	Director	Apr 23	Sale	272.53	2,000	545,052	1,875	Apr 24 04:17 PM
Lee Yuchun	Director	Apr 22	Option Exercise	57.27	2,000	114,540	3,875	Apr 24 04:17 PM
Lee Yuchun	Director	Apr 22	Sale	267.88	2,000	535,753	1,875	Apr 24 04:17 PM
Lee Yuchun	Director	Apr 21	Option Exercise	57.27	2,000	114,540	3,875	Apr 22 04:14 PM
Lee Yuchun	Director	Apr 21	Sale	266.76	2,000	533,523	1,875	Apr 22 04:14 PM
Lee Yuchun	Director	Apr 20	Option Exercise	57.27	2,000	114,540	3,875	Apr 22 04:14 PM
Lee Yuchun	Director	Apr 20	Sale	273.16	2,000	546,310	1,875	Apr 22 04:14 PM
Silva Paul M	SVP & Controller	Apr 13	Option Exercise	90.29	859	77,559	15,791	Apr 15 04:15 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience